Form 4 for RVMD Revolution Medicines, Inc.
Accepted 2024-05-03 00:00:00 ET · period of report 2024-05-03 · accession 0001610717-24-000229 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-05-03 | 2024-05-03 | RVMD | Anders Jack | CFO | S - Sale+OE | $40.03 | -10.0K | 102.0K | -9% | -$400.3K |
| DT | 2024-05-03 | 2024-05-03 | RVMD | Anders Jack | CFO | M - OptEx | $2.68 | +10.0K | 112.0K | +10% | +$26.8K |
| DT | 2024-05-03 | 2024-05-03 | RVMD | Anders Jack | CFO | M - OptEx | $0.00 | -10.0K | 12.8K | -44% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-03 | S | D | 10,000 | $40.03 | 101,959 | D | — | — | (F3) This transaction was executed in multiple trades in prices ranging from $40.00 to $40.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F2) Includes 60,250 restricted stock units. |
| 2 | Common | Common Stock | 2024-05-03 | M | A | 10,000 | $2.68 | 111,959 | D | — | — | (F2) Includes 60,250 restricted stock units. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-05-03 | M | D | 10,000 | $0.00 | 12,814 | D | $2.68 · 2022-08-16 to 2028-09-26 | 10,000 Common Stock |